Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults

Key Inclusion Criteria:

- Plasma HIV-1 RNA ≥ 10,000 copies/mL but ≤ 400,000 copies/mL and CD4+ cell count > 200
cells/mm^3

- Treatment naive or experienced but CAI and integrase strand transfer inhibitor (INSTI)
naïve, and have not received any antiretroviral therapy (ART) within 12 weeks of
screening

- Screening genotype report must show sensitivity to B/F/TAF to allow its initiation on
Day 10

- Screening genotype report must show sensitivity to at least one agent in either
non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI)
class to allow its use as part of standard of care oral antiretroviral treatment in
the future

- Have adequate renal function (estimated glomerular filtration rate ≥ 70 mL/min)

- No clinically significant abnormalities in ECG at Screening

- Willing to initiate B/F/TAF on Day 10 after completion of all assessments

Key Exclusion Criteria:

- Pregnant or lactating

Note: Other protocol defined Inclusion/Exclusion criteria may apply.